The Association of Circulating Bone Morphogenetic Protein 9 and Arterial Stiffness in Hypertensive Patients

Sijin Zhang1, Mingjie Ma2, Ping Li2

  • 1School of Medcine, Nankai University, Tianjin, China.

Bone morphogenetic protein 9 (BMP9) plays an important role in vascular development and stability. However, the association between circulating BMP9 levels and arterial stiffness (AS) in hypertensive patients is not yet clear. This study enrolled 305 hospitalized patients with hypertension. Brachial-ankle pulse wave velocity (baPWV) was measured, with values ≥1800 cm/s indicating AS. Clinical characteristics and laboratory parameters were collected during hospitalization. Circulating BMP9 levels were measured with an ELISA kit. Multivariable linear regression and stepwise logistic regression analysis were used to assess the relationship between BMP9 and baPWV. A nomogram was constructed to predict AS in hypertensive patients and internally validated using the bootstrap method. Among 305 patients, 97 were diagnosed with AS. Multivariable linear regression analysis revealed that BMP9 was positively correlated with baPWV in hypertensive patients (β = 0.471, p < 0.001). Multivariate logistic stepwise regression analysis showed that age ≥ 60 years old, diabetes mellitus, SBP ≥ 140 mmHg, and higher BMP9 levels were the independent risk factors for hypertensive patients with AS. A nomogram combining these factors showed strong predictive performance (AUC: 0.804, 95% CI: 0.7503-0.8567). The calibration plot performed a good adaptability between prediction and observation (χ2 = 6.60, p = 0.359) and the decision curve analysis (DCA) demonstrated the acceptable clinical utility. The addition of BMP9 to the traditional risk model had an incremental effect on the predictive value for AS (0.765 vs. 0.804, p < 0.01). The elevation of BMP9 is strongly related to AS in hypertensive patients. BMP9 may be a biomarker of AS in hypertension.

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
58
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
4.0K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
90
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
38
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.1K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
222